Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-Label, Multicenter, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NVC-001, a Novel Adeno-Associated Virus (Serotype 9) Vector Expressing a Dominant Negative SUN1 Transgene, in Patients With LMNA-Related Dilated Cardiomyopathy (SUNBEAM-LMNA)

NCT07606274 is registered in ClinicalTrials.gov with Nuevocor Pte. Ltd. as lead sponsor.

NCT NCT07606274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07606274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-Label, Multicenter, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NVC-001, a Novel Adeno-Associated Virus (Serotype 9) Vector Expressing a Dominant Negative SUN1 Transgene, in Patients With LMNA-Related Dilated Cardiomyopathy (SUNBEAM-LMNA)
Lead sponsor
Nuevocor Pte. Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 16, 2026
Completion date
March 31, 2030
Enrollment
21 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

lmna-related dilated cardiomyopathy